Deerfield Management Company, L.P. (Series C) Larimar Therapeutics, Inc. Call Options Transaction History
Deerfield Management Company, L.P. (Series C)
- $4.35 Billion
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding LRMR
# of Institutions
129Shares Held
65.9MCall Options Held
4.83MPut Options Held
83.7K-
Ra Capital Management, L.P. Boston, MA6.05MShares$25.9 Million0.38% of portfolio
-
Blue Owl Capital Holdings LP New York, NY4.93MShares$21.1 Million7.71% of portfolio
-
Opaleye Management Inc. Boston, MA4.11MShares$17.6 Million2.84% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.66MShares$15.7 Million0.01% of portfolio
-
Chi Advisors LLC New York, NY3.41MShares$14.6 Million6.65% of portfolio
About Larimar Therapeutics, Inc.
- Ticker LRMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,269,200
- Market Cap $186M
- Description
- Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...